CoChat
Sign Up
Cited by 40Pancreatic and Hepatic Oncology ResearchComplement system in diseasesPancreatitis Pathology and Treatment

Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer

Open access
CHEN, JIONG, WU, WEN, ZHEN, CHUNSHENG, ZHOU, HANGCHEN, YANG, RENBAO, CHEN, LONGJIANG, HU, LIWEI·2013·Oncology Letters
DOI 10.3892/ol.2013.1326PMC PMC3742809
Open this paper in CoChat — free accountOpen PDF

Abstract

Pancreatic cancer (PC) remains a devastating disease with a five-year survival rate of <5%. The difficulty in making an early diagnosis and the frequent occurrence of metastasis are important reasons for this poor prognosis. In China, the incidence of PC has been increasing steadily. Therefore, the present study aimed to identify effective markers in the early and advanced stages of PC. The expression levels of complement C3, complement C4b1 and apolipoprotein E (ApoE) in the various stages of PC were assessed by immunohistochemistry, RT-PCR and western blotting. Additionally, the statistical significance of the results was analyzed. The expression levels of complement C3, complement C4b1 and apoE were higher in PC compared with normal pancreatic tissues. No correlations were observed between complement C3 and tumor TNM staging or lymph node metastasis. However, complement C4b1 and apoE were markedly correlated with tumor TNM staging and lymph node metastasis. Complement C3 may be used as a marker for the diagnosis of early-stage PC, while complement C4b1 and apoE are closely correlated with tumor development, reflecting the biological behavior of PC, and thus may be used as diagnostic markers of advanced PC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2013.1326

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mechanisms underlying the association between high apoE levels and increased cancer mortality could likely be due to apoE involvement in metastasis and angiogenesis.

    “mechanisms underlying the association between high apoE levels and increased cancer mortality could likely be due to apoE involvement in metastasis and angiogenesis.49–56”

    From Plasma levels of apolipoprotein E, <i>APOE</i> genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort (2019) · cites this paper as [54]

    The Discussion reports higher ApoE levels in pancreatic tumors with lymph-node metastasis than in those without it, supporting an association with metastasis. It does not establish that ApoE causes metastasis, or report an angiogenesis mechanism or an association between ApoE levels and cancer mortality. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. [1]Guo X Cui Z Current diagnosis and treatment of pancreatic cancer in China Pancreas 31 13 22 2005 15968242
  2. [2]Willett CG Daly WJ Warshaw AL CA 19–9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer Am J Surg 172 350 352 1996 8873528
  3. [3]Goonetilleke KS Siriwardena AK Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol 33 266 270 2007 17097848
  4. [4]Marrelli D Caruso S Pedrazzani C CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions Am J Surg 198 333 339 2009 19375064
  5. [5]Grønborg M Bunkenborg J Kristiansen TZ Comprehensive proteomic analysis of human pancreatic juice J Proteome Res 3 1042 1055 2004 15473694
  6. [6]Cecconi D Palmieri M Donadelli M Proteomics in pancreatic cancer research Proteomics 11 816 828 2011 21229586
  7. [7]Hugli TE Structure and function of the anaphylatoxins Springer Semin Immunopathol 7 193 219 1984 6387982
  8. [8]Scholz W McClurg MR Cardenas GJ C5a-mediated release of interleukin 6 by human monocytes Clin Immunol Immunopathol 57 297 307 1990 2208809
  9. [9]Wang W Abbruzzese JL Evans DB The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin Cancer Res 5 119 127 1999 9918209
  10. [10]Habermann JK Roblick UJ Luke BT Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors Gastroenterology 131 1020 1029 2006 17030172 PMC2532535
  11. [11]Pickering MC Botto M Taylor PR Systemic lupus erythematosus, complement deficiency, and apoptosis Adv Immunol 76 227 324 2000 11079100
  12. [12]Einav S Pozdnyakova OO Ma M Carroll MC Complement C4 is protective for lupus disease independent of C3 J Immunol 168 1036 1041 2002 11801636
  13. [13]Fujita T Hara A Yamazaki Y The value of acute-phase protein measurements after curative gastric cancer surgery Arch Surg 134 73 75 1999 9927135
  14. [14]Greenow K Pearce NJ Ramji DP The key role of apolipoprotein E in atherosclerosis J Mol Med (Berl) 83 329 342 2005 15827760
  15. [15]Trompet S Jukema JW Katan MB Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study Am J Epidemiol 170 1415 1421 2009 19889709
  16. [16]Trost Z Marc J Sok M Cerne D Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients Arch Med Res 39 663 667 2008 18760194
  17. [17]Grant WB A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor Anticancer Res 30 189 199 2010 20150635
  18. [18]Andreotti G Chen J Gao YT Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China Cancer Epidemiol Biomarkers Prev 17 525 534 2008 18296645 PMC2897750
  19. [19]Moore LE Brennan P Karami S Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk Cancer Res 69 8001 8008 2009 19808960 PMC2793179
  20. [20]Beppu T Gil-Bernabe P Boveda-Ruiz D High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice J Tromb Haemost 8 2514 2522 2010 20723031
  21. [21]Mrkonjic M Chappell E Pethe VV Association of apolipoprotein E polymorphisms and dietary factors in colorectal cancer Br J Cancer 100 1966 1974 2009 19455140 PMC2714237
  22. [22]Grønborg M Kristiansen TZ Iwahori A Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach Mol Cell Proteomics 5 157 171 2006 16215274
  23. [23]Yu KH Rustgi AK Blair IA Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry J Proteome Res 4 1742 1751 2005 16212428
  24. [24]Gillard BK Lin HY Massey JB Pownall HJ Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells Biochim Biophys Acta 1791 1125 1132 2009 19635584 PMC2783830
  25. [25]Huvila J Brandt A Rojas CR Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors Int J Gynecol Cancer 19 1226 1231 2009 19823059
  26. [26]Martínez-Clemente M Ferré N González-Périz A 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice Hepatology 51 817 827 2010 20112424

Cited by

Sorted by citations

Authors
CHEN, J., WU, W., ZHEN, C., ZHOU, H., YANG, R., CHEN, L., & HU, L.
Affiliations
Anhui Medical University (CN)
Corresponding author
CHEN, JIONG
ORCID
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2013-04-30
Volume
6
Issue
1
Pages
43-48
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
DOI
10.3892/ol.2013.1326
PMC
PMC3742809
OpenAlex
W2002359694
Cited by
40
References
0
Citations by year
2026: 2 · 2025: 5 · 2024: 5 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 4
FWCI
1.43
Type
journal article
Language
en
Open access
Locations
  • Oncology Letters (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic cancer, complement C3, apolipoprotein E, tumor markers, TNM staging, lymph node metastasis, early diagnosis, tumor progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review